Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;70(2):e30075.
doi: 10.1002/pbc.30075. Epub 2022 Nov 9.

Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma

Kathryn R Tringale  1 , Suzanne L Wolden  1 , Dana L Casey  2 , Brian H Kushner  3 , Leo Luo  4 , Neeta Pandit-Taskar  5 , Mark Souweidane  6 , Nai-Kong V Cheung  3 , Shakeel Modak  3 , Ellen M Basu  3 , Kim Kramer  3
Affiliations

Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma

Kathryn R Tringale et al. Pediatr Blood Cancer. 2023 Feb.

Abstract

Background: In high-risk neuroblastoma, multimodality therapy including craniospinal irradiation (CSI) is effective for central nervous system (CNS) relapse. Management of post-CSI CNS relapse is not clearly defined.

Procedure: Pediatric patients with neuroblastoma treated with CSI between 2000 and 2019 were identified. Treatment of initial CNS disease (e.g., CSI, intraventricular compartmental radioimmunotherapy [cRIT] with 131 I-monoclonal antibodies targeting GD2 or B7H3) and management of post-CSI CNS relapse ("second CNS relapse") were characterized. Cox proportional hazards models to evaluate factors associated with third CNS relapse and overall survival (OS) were used.

Results: Of 128 patients (65% male, median age 4 years), 19 (15%) received CSI with protons and 115 (90%) had a boost. Most (103, 81%) received cRIT, associated with improved OS (hazard ratio [HR] 0.3, 95% confidence interval [CI]: 0.1-0.5, p < .001). Forty (31%) developed a second CNS relapse, associated with worse OS (1-year OS 32.5%, 95% CI: 19-47; HR 3.8; 95% CI: 2.4-6.0, p < .001), and more likely if the leptomeninges were initially involved (HR 2.5, 95% CI: 1.3-4.9, p = .006). Median time to second CNS relapse was 6.8 months and 51% occurred outside the CSI boost field. Twenty-five (63%) patients underwent reirradiation, most peri-operatively (18, 45%) with focal hypofractionation. Eight (20%) patients with second CNS relapse received cRIT, associated with improved OS (HR 0.1; 95% CI: 0.1-0.4, p < .001).

Conclusions: CNS relapse after CSI for neuroblastoma portends a poor prognosis. Surgery with hypofractionated radiotherapy was the most common treatment. Acknowledging the potential for selection bias, receipt of cRIT both at first and second CNS relapse was associated with improved survival. This finding necessitates further investigation.

Keywords: craniospinal irradiation; intraventricular compartmental radioimmunotherapy; neuroblastoma; pediatric cancers; radiotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Choi HS, Koh SH, Park ES, Shin HY, Ahn HS. CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma. Pediatr Blood Cancer. 2005;45:68-71. https://doi.org/10.1002/pbc.20315
    1. DuBois S, Kalika Y, Lukens J, Al E. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21:181-189.
    1. Kramer K, Kushner B, Heller G, Cheung NV. Neuroblastoma metastatic to the central nervous system. Cancer. 2001;91(8):1510-9. https://doi.org/10.1002/1097-0142(20010415)91:8<1510::aid-cncr1159&gt...
    1. Matthay KK, Brisse H, Couanet D, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003;98:155-165. https://doi.org/10.1002/cncr.11448
    1. Croog VJ, Kramer K, Cheung NKV, et al. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2010;78:849-854. https://doi.org/10.1016/j.ijrobp.2009.09.005